Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 11/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 11/20 | 0.40 |
| ▸ | ITGAL | P20701 | 11/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310400 | 0.88 | ITGAL (0.43) | ITGB2ICAM1ITGALNOTUMSERPINE1 | |
| SCHEMBL6311168 | 0.87 | NOTUM (0.41) | ITGB2ICAM1ITGALNOTUMSERPINE1 | |
| SCHEMBL6405999 | 0.87 | ITGB2 (0.51) | ITGB2ICAM1ITGAL | |
| SCHEMBL6308747 | 0.86 | NOTUM (0.39) | ITGB2ICAM1ITGALNOTUMPDK2 | |
| SCHEMBL6311400 | 0.83 | ITGB2 (0.58) | ITGB2ICAM1ITGAL | |
| SCHEMBL6568656 | 0.83 | ITGB2 (0.58) | ITGB2ICAM1ITGAL | |
| SCHEMBL6817904 | 0.80 | NPC1 (0.32) | ITGB2ICAM1ITGAL | |
| SCHEMBL6317150 | 0.79 | ITGB2 (0.38) | ITGB2ICAM1ITGALNOTUMSERPINE1 | |
| SCHEMBL6308904 | 0.78 | ITGB2 (0.47) | ITGB2ICAM1ITGALNOTUM | |
| SCHEMBL6311938 | 0.78 | ITGB2 (0.40) | ITGB2ICAM1ITGALNOTUMSERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | claimed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1481968-A2 | Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds | Abbott Laboratories (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| EP-1165505-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059880-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | ITGB2 32/4885ICAM1 1/4885ITGAL 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.